TP53 and endometrial cancer: More importantly, ATR inhibitors and platinum generated synergistic cytotoxicity in p53-wild or p53-mutant platinum-resistant tumor cell lines, which provided a great treatment strategy for newly diagnosed or recurrent ovarian, cervical, and endometrial cancers [61].